Conatus Pharmaceuticals   Report issue

For profit Phase 2
Founded: San Diego CA United States (2005)
Status: Acquired by Histogen (2020)

Organization Overview

First Clinical Trial
2005
NCT00080236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Conatus Pharmaceuticals | Conatus Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

Key: Conatus Pharmaceuticals (3) Acquired (1)

cts-1027 (4 trials)

emricasan (16 trials)

interferon alpha-2b (Intron-A) (2 trials)

ribavirin (virazole) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Cholestasis (Phase 2)

Digestive System Diseases (Phase 1)

Fatty Liver (Phase 2)

Fibrosis (Phase 2)

Gastrointestinal Diseases (Phase 1)

Hepatic Insufficiency (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypertension (Phase 2)

Hypertension, Portal (Phase 2)

Kidney Diseases (Phase 1)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 2)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Renal Insufficiency (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 20
  • # of Trial APIs: 4